OUR VISION IS TO REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES WORLDWIDE.

News

Keep up to date with the latest news items from GAFFI.

Two point-of-care tests for invasive aspergillosis launched

Posted .

Prompt initiation of antifungal therapy can make the difference between life and death for patients with invasive aspergillosis. Point-of-care diagnostics (POC; a.k.a. ‘bedside testing’) allows clinicians to begin treatment right away while awaiting confirmation by culture and histological examination. Two companies have released affordable and simple to use POC tests for invasive aspergillosis. Both tests… Read more »

Read more >

WHO releases its first Essential Diagnostic List

Posted .

Following its Advisory meeting in April 2018, the World Health Organisation (WHO) has issued its first listing of Essential Diagnostics. The list is split into general laboratory tests (n= 58) and specific tests for key infections (HIV, TB, hepatitis, syphilis and human papilloma virus) (n=55). It is also split into sections relating to testing in… Read more »

Read more >

GAFFI annual report released alongside burden of fungal diseases estimates for Benin and Sweden

Posted .

GAFFI released its 2017 annual report at the European Conference of Clinical Microbiology and Infectious Diseases (ECCMID) following its Board meeting. GAFFI’s Guatemala program takes centre stage showing the immediate diagnostic benefits of rapid screening of ill patients with HIV infection for AIDS for cryptococcal diseases, histoplasmosis and tuberculosis. Other highlights from 2017 include inclusion… Read more »

Read more >

Flucytosine takes centre stage for cryptococcal meningitis in AIDS

Posted .

In a happy coincidence March 15th marks 2 major steps forward in treating fungal meningitis in AIDS. The World Health Organization has accepted the pre-qualification of flucytosine application from Mylan. This means greatly accelerated approval of this life-saving drug in at least 32 countries, in a very short time frame. Dr Sile Molloy (St, George’s… Read more »

Read more >

Global health improvement targets announced on World Aspergillosis Day

Posted .

Aspergillosis, lung and sinus disease caused by the fungus Aspergillus, affects around 15 million people and kills over 1 million each year.  Announced today at the 8th biennial Advances against Aspergillosis international conference in Lisbon starting on February 1st, are the 5 aspirational targets for aspergillosis to be achieved by 2030: Survival in invasive aspergillosis… Read more »

Read more >

Histoplasmosis in Africa is under-recognised and under-reported

Posted .

Dr Rita Oladele, GAFFI’s Ambassador in Nigeria has highlighted a worrying lack of diagnosis and reporting of histoplasmosis in African countries. Despite being an AIDS-defining infection, much basic information about histoplasmosis is lacking, including accurate incidence/prevalence rates, morbidity/mortality rates, and outcomes. This is due to haphazard reporting in regions with more basic laboratory and imaging… Read more »

Read more >

Havana meeting on the Neglected Tropical Fungal Disease Chromoblastomycosis, calls on Public Health authorities to take action

Posted .

Havana, 11th December:  (Read this in Spanish). Alongside the 80th anniversary of the Cuban Tropical Medicine Institute, 200 scientists and doctors sought common actions to reduce the stigmatizing burden of chromoblastomycosis. This persistent and progressive fungal infection is usually caused by a trivial injury, usually on the leg or arm, and has recently been recognised… Read more »

Read more >